Headquartered in New York, NY Fiscal year ends December NYSE: PFE pfizer.com
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide. The company operates primarily through its Global Biopharmaceuticals Business (Biopharma) segment and Pfizer CentreOne contract manufacturing division. Its commercial structure includes the Pfizer U.S. Commercial Division, the Pfizer International Commercial Division, and the Global Hospital and Biosimilars Division. Pfizer's portfolio spans primary care (including Eliquis for blood clots, the Prevnar pneumococcal vaccine family, Comirnaty COVID-19 vaccine, Paxlovid antiviral, and Abrysvo RSV vaccine), oncology (including Ibrance for breast cancer, Padcev for urothelial and bladder cancer, Xtandi for prostate cancer, Lorbrena for ALK+ lung cancer, and several other targeted therapies), and specialty care (including the Vyndaqel family for transthyretin amyloid cardiomyopathy, Xeljanz, and Cibinqo). The company also markets biosimilars and operates a contract manufacturing business. Pfizer has a robust late-stage pipeline including berobenatide, a potential first-in-class monthly GLP-1 receptor agonist for obesity, a 25-valent pneumococcal conjugate vaccine candidate, and sigvotatug vedotin in multiple oncology settings. Pfizer recently entered a strategic licensing and collaboration agreement with Innovent Biologics for 12 early-stage cancer medicines including antibody-drug conjugates and multi-specific antibodies. Updated
Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.
Pfizer just marked a fresh 52-week high at $29.02, 1.58% above the peak it set on Aug. 25. Anyone anchored to the low-$23 range from a year ago is now looking at a very different reference point.
Seven names printed fresh 52-week highs this week, spanning travel, software and defensives. Box led with a 3.98% clearance over its prior peak, with Coca-Cola, Pfizer, Airbnb and Expedia also at new records.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
Pfizer closed at $28.24, a new 52-week high that clears the April 1 peak. The drugmaker has now taken out the ceiling that capped it all spring, making that old level the line to defend.
Investors are only learning now, 521 days late, that a Ways and Means Republican's household cleared out four positions on the same March 2025 day, including two healthcare names her committee legislates on. The filing lag is the story: disclosure rules give 45 days, and this one took more than a year past that.
Six dividend stocks in a $500,000 portfolio sound like a solid income plan, but where you hold them decides how much of that income you actually keep, and the difference compounds into…
Retirees chasing income face a choice that looks simple on paper but hides a tax trap, a reinvestment problem, and a dividend cut risk that most income comparisons never mention.
A portfolio built entirely around stocks and equity funds can generate $12,300 a month, or $147,600 a year, in income. The no-bond design stands out with the 10-year Treasury yielding 5.2%. Using…
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine…
Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVie, Merck, and Pfizer, but higher targets do not mean equal conviction. The firm's split between Overweight and Neutral ratings reveals a sharp…
Four household names are dangling yields above 5% at a moment when their earnings, cash flow, and debt levels raise serious questions about whether those payouts can last. Retirees counting on that…
When the paycheck stops at retirement, your portfolio has to carry the weight, and one dividend cut can force painful choices between a tighter budget and selling shares at the worst moment.…
Pfizer's yield towers over Johnson and Johnson's, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a…
Johnson & Johnson just logged its 64th straight year of dividend growth, but biosimilar threats, a MedTech slowdown, and lingering talc litigation raise a real question about whether that streak justifies buying…
Some of the most recognizable dividend stocks in the market have been paying shareholders with money they do not actually earn, and the accounting trail reveals exactly how far six of them…
Moderna stock has turned a handful of patient shareholders into believers, but a gain this size forces a choice that most investors never plan for in advance. The pipeline promise is real,…
A plague headline out of Siberia lifted vaccine stocks, and the agencies closest to the case have since described the risk as low. That reversal in sentiment lands hardest on Novavax (NASDAQ:NVAX),…
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are trading as though the company’s messenger RNA (mRNA) cancer vaccine has already cleared its final test, even though the complete Phase 3 dataset…
Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that…
Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture, marketing, sale, and distribution of biopharmaceutical products worldwide.
24/7 Wall St.'s 12-month price target for PFE is $32.95, rated Buy. The Wall Street consensus target is $29.11. PFE price prediction →
